Piper Sandler Maintains Overweight on NeoGenomics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg has maintained an Overweight rating on NeoGenomics (NASDAQ:NEO) but lowered the price target from $23 to $18.
October 16, 2023 | 5:30 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler has maintained an Overweight rating on NeoGenomics but lowered the price target from $23 to $18.
The news is directly about NeoGenomics and is likely to impact its stock. While the Overweight rating suggests that the stock is expected to outperform, the lowering of the price target may create some negative sentiment among investors. However, the overall impact is neutral as the Overweight rating is maintained.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100